Fundación Española del Dolor Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2020
NCT04299893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Fundación Española del Dolor (FED)

Active Ingredients

Drugs in Phase 3 Trials (2)

oxygen (1 trial)

ozone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuralgia (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2